Pfizer Incyesterday shared results from multiple studies demonstrating the in-vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of Paxlovid, is maintained against the omicron ...
Source LinkPfizer Incyesterday shared results from multiple studies demonstrating the in-vitro efficacy of nirmatrelvir, the active main protease (Mpro) inhibitor of Paxlovid, is maintained against the omicron ...
Source Link
Comments